I can only speak to the impact that these two clauses have on regulated medical devices. We have equal concern with regard to clause 1 and clause 2, specifically around the parts components in clause 2. As you know, some components of medical devices go into contact with humans—blood, for instance, and solutions that go into human patients—and that's something we'd be equally concerned about as going into software, as mentioned in clause 1.
I'm not sure if I answered your question. If not, please feel free to ask it again.